Choosing the right lipid-regulating agent: A guide to selection

Drugs

Volumn 52, Issue 5, 1996, Pages 649-661

  Farmer, John A ^a   Gotto Jr , Antonio M ^b,c  

^a BEN TAUB GENERAL HOSPITAL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BEZAFIBRATE; BILE ACID; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIGITALIS; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; THYROID HORMONE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENTEROHEPATIC CIRCULATION; ENZYME ACTIVITY; FLATULENCE; HEALTH STATUS; HEPATITIS; HOT FLUSH; HUMAN; INDIGESTION; LIFESTYLE; LIPID BLOOD LEVEL; LIVER TOXICITY; META ANALYSIS; METABOLIC DISORDER; MYOSITIS; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRURITUS; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; TREATMENT PLANNING;

DIGITALIS;

EID: 0029828384     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00003     Document Type: Review

References (59)

1. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-445
2. Farmer JA, Gotto Jr AM. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab 1995; 9: 825-47
3. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33
4. Kostner GM, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-9
5. Tsuda Y, Satoh K, Takahashi T, et al. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia. Int Angiol 1993; 12: 360-4
6. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Intern Med 1990; 227: 365-72
7. Isaacsohn JL, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74: 735-7
8. Wada H, Mori Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112-6
9. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
12. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419-25
13. Kirby TJ. Cataracts produced by triparanol. Trans Am Ophthalmol Soc 1967; 65: 493-543
14. Tobert JA, Shear CL, Chremos AN, et al. Clinical experience with lovastatin. Am J Cardiol 1990; 65: 23F-6F
15. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
16. Spach DH, Bauwens JE, Clark CD, et al. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213-6
17. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41
18. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol 1990; 30: 99-106
19. 14C and its degradation products in a hypercholesterolemic patient. J Clin Invest 1968; 47: 1664-71
20. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
21. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98
22. Gallo DG, Bailey KR, Sheffner AL. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 1965; 120: 60-5
23. Bazzano G, Bazzano GS. Digitalis intoxication: treatment with a new steroid-binding resin. JAMA 1972; 220: 828-30
24. Northcutt RC, Stiel JN, Hollifield JW, et al. The influence of cholestyramine on thyroxine absorption. JAMA 1969; 208: 1857-61
25. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987; 2: 10-32
26. Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol 1982; 20: 151-4
27. Shepherd J, Packard CJ, Patsch JR, et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63: 858-67
28. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-6
29. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81
30. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
31. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18
32. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989; 111: 253-5
33. Lilin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989; 86: 481-3
34. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis [letter]. Ann Intern Med 1988; 109: 597-8
35. Brown WV, Howard WJ, Field L. Nicotinic acid and its derivatives. In: Rifkind BM, editor. Drug treatment of hyperlipidemia. New York. Marcel Dekker, 1991; 189-213
36. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92: 77-81
37. Nikkila EA, Huttunen JK, Ehnholm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 1977; 26: 179-86
38. Levy RI, Morganroth J, Rifkind BM. Treatment of hyperlipidemia. N Engl J Med 1976; 290: 1295-301
39. Davignon J. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994; 10 Suppl.B: 61B-71B
40. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21
41. Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis 1992; 95: 35-42
42. Eisenberg S, Gavish D, Oschry Y, et al. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment. J Clin Invest 1984; 74: 470-82
43. Bo M, Bonino F, Neirotti M, et al. Hemorrheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106-13
44. Andersen P, Smith P, Seljeflot I, et al. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63: 174-7
45. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
46. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37-45
47. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-118
48. Illingworth DR. Fibric acid derivatives. In: Rifkind BM, editor. Drug treatment of hyperlipidemia. New York: Marcel Dekker, 1991: 103-38
49. Sirtori CR, Calabresi L, Werba JP, et al. Tolerability of fibric acids. Comparative data and biochemical bases. Pharmacol Res 1992; 26: 243-60
50. Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968; 279: 856-8
51. Baker SG, Joffe BI, Mendelsohn D, et al. Treatment of homozygous familial hypercholesterolemia with probucol. S Afr Med J 1982; 62: 7-11
52. Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57: 29H-35H
53. Schmidt EB, Illingworth DR, Bacon S, et al. Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. Metabolism 1993; 42: 137-9
54. Grundy SM. Multifactorial etiology of hypercholesterolemia: implications for prevention of coronary heart disease. Arterioscler Thromb 1991; 11: 1619-35
55. American Diabetes Association. Detection and management of lipid disorders in diabetes. Diabetes Care 1993; 16 Suppl. 2: 106-12
56. Juhan-Vague I, Roul C, Alessi M, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 1989; 61: 370-3
57. Prata MM, Nogueira AC, Pinto JR, et al. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Clin Nephrol 1994; 41: 277-83
58. Knight RJ, Vathsala A, Schoenberg L, et al. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation 1992; 53: 224-5
59. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7